Mega Lifesciences 1H 2025 slides: Revenue drops 14% as Myanmar weighs on distribution business

Mega Lifesciences PCL reported a 14.0% revenue decline to THB 6,607 million for 1H25, primarily driven by a 34.4% drop in its MAXXCARE™ distribution business in Myanmar. Despite this, the higher-margin MEGA WE CARE™ branded products segment grew 2.6%, improving the overall gross margin to 51.5% due to a favorable revenue mix. Adjusted net profit decreased 12.4% to THB 920.5 million, yet operating cash flow surged 46.5%. The company is strategically addressing regional challenges by expanding its branded product portfolio and investing THB 495 million in an Indonesian manufacturing facility, signaling a pivot towards higher-margin growth and long-term profit expansion despite immediate headwinds.

Analysis

Mega Lifesciences PCL (SET:MEGA) reported a challenging first half for 2025, with total operating revenue declining 14.0% year-over-year to THB 6,607 million, leading to a 12.4% fall in adjusted net profit to THB 920.5 million. The primary driver of this downturn was a severe 34.4% contraction in the MAXXCARE™ distribution business, directly linked to operational difficulties in Myanmar. However, this weakness was partially offset by the resilience of the MEGA WE CARE™ branded products segment, which grew 2.6% and now represents a more dominant 63.2% of total revenue, up from 53.0% in the prior year. This strategic shift in the revenue mix favorably impacted profitability, lifting the overall gross margin to 51.5% from 47.7%, although the branded segment itself saw a minor margin compression to 63.8%. Despite the profit decline, the company's financial foundation remains robust, evidenced by a 46.5% surge in operating cash flow and a strong net cash position. Management is actively pivoting away from its current vulnerabilities by investing THB 495 million in a new Indonesian manufacturing facility and preparing to launch over 120 new products, signaling a clear long-term strategy focused on higher-margin segments in new geographic markets.

Key Decisions for Investors

• Investors should weigh the near-term revenue headwinds from the Myanmar distribution business against the company's strategic pivot towards the higher-margin, growing branded products segment and its expansion into Indonesia.
• Monitor the revenue growth rate of the MEGA WE CARE™ segment and overall gross margin trends in the coming quarters as key indicators of successful strategy execution.
• Given the stock is trading 29% below its 52-week high, the current valuation may offer an attractive entry point for long-term investors who believe in the company's strong balance sheet, robust cash flow, and ability to execute on its geographic and product expansion plans.